The blue-chip multinational has a good mix of prescription and over-the-counter products, which makes it well-suited to weather volatility. Shares of Johnson & Johnson sank 1.72% on Tuesday following softer-than-expected guidance for 2017.

Actelion said on Wednesday it has entered exclusive negotiations with U.S. healthcare company Johnson & Johnson regarding what the Swiss biotech company called a “possible strategic transaction”.